mediQuo an eHealth Startup Closes €2M Funding Round

mediQuo, the leading eHealth app in Spain and Latin America, secured an investment of 2 million euros at the beginning of January 2020, from several renowned investors from the health sector as well as from various Venture Capital investors and Family Offices, with a track record in the digital health space.

All existing investors have joined the round. With the new funding round, which includes all current shareholders, mediQuo can continue its momentum as the leading company in the Spanish medical startup sector.

mediQuo also announces an exciting addition to its management team. Bruno Cuevas will join the company as Co-CEO, along with founder and Co-CEO Dr Guillem Serra. Bruno is the former Vice President of Global Markets at Adevinta/Schibsted, a global group of leading online marketplaces, where he was responsible for an international portfolio of operations in Europe, Asia, Latin America and North Africa. He has also been board member in numerous international marketplaces, including Schibsted Spain (Fotocasa, Infojobs, Milanuncios, coches.net, etc.). Before Adevinta, he worked at Groupon and in strategy consulting.

mediQuo will soon launch its mediQuo PRO app, which will allow doctors and health professionals to manage consultations online for both their own patients as well as for the users of the app. This is in compliance with the European GDPR regulation at all times, thus reinforcing patient and doctor confidentiality. With the launch of mediQuo PRO the company aims to reach a total of 14,000 health professionals and to be able to manage 1.5 million patient consultations within the next 15 months.

mediQuo founder Dr Guillem Serra says: “The recent funding round and the launch of the new app are major boosts to the growth of the platform and to fulfill our purpose to foster the digitization of medicine and healthcare. We are happy to have Bruno Cuevas, joining the team. With his proven track record developing and managing international marketplaces, we are going to take a giant step forward.”

Bruno Cuevas says: “mediQuo wants to change the way in which patients interact with health professionals, thus improving people’s lives. We have a great team, the required technology, knowledge of the health arena as well as of how to operate marketplaces, and the support of renowned investors within the sector. Our ambition is as great as the company’s potential, and with this funding round we have set out to deeply change the health sector – to place a hospital in each person’s pocket.”

This Spanish startup was founded by Guillem Serra, a medical doctor, mathematician, founder and investor in multiple startups, together with Albert Castells and José López, also founders of iSalud.com. Since its launch 2 years ago, mediQuo has received 4 million euros in funding. Its app has been installed by nearly 600,000 users and has been able to manage nearly one million medical consultations, multiplying by 10 the sale of premium subscriptions over the last year.

SourcemediQuo

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”